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Background: Azelastine has been shown to be effective against seasonal allergic rhinitis (SAR). The Environmental
Exposure Unit (EEU) is a validated model of experimental SAR. The objective of this double-blind, four-way
crossover study was to evaluate the onset of action of azelastine nasal spray, versus the oral antihistamines
loratadine 10 mg and cetirizine 10 mg in the relief of the symptoms of SAR.
Methods: 70 participants, aged 18-65, were randomized to receive azelastine nasal spray, cetirizine, loratadine, or
placebo after controlled ragweed pollen exposure in the EEU. Symptoms were evaluated using the total nasal symptom
score (TNSS). The primary efficacy parameter was the onset of action as measured by the change from baseline in TNSS.
Results: Azelastine displayed a statistically significant improvement in TNSS compared with placebo at all time points
from 15 minutes through 6 hours post dose. Azelastine, cetirizine, and loratadine reduced TNSS compared to placebo
with an onset of action of 15 (p < 0.001), 60 (p = 0.015), and 75 (p = 0.034) minutes, respectively. The overall assessment
of efficacy was rated as good or very good by 46% of the participants for azelastine, 51% of the participants for
cetirizine, and 30% of the participants for loratadine compared to 18% of the participants for placebo.
Conclusions: Azelastine’s onset of action for symptom relief was faster than that of cetirizine and loratadine. The overall
participant satisfaction in treatment with azelastine is comparable to cetirizine and statistically superior to loratadine.
These results suggest that azelastine may be preferential to oral antihistamines for the rapid relief of SAR symptoms.
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Seasonal allergic rhinitis (SAR) is an inflammatory disease
characterized by multiple symptoms including sneezing,
rhinnorhea, nasal congestion, nasal and nasopharyngeal
itching, and has associated ocular symptoms such as itchy,
watery and red/burning eyes [1]. Oral antihistamines are
often the first line treatment administered for SAR [2].
However, as SAR symptoms result from an interaction* Correspondence: ellisa@queensu.ca
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reproduction in any medium, provided the orbetween inhaled allergens and IgE antibodies on mast cells
located in the upper airway [3], it may be possible to
achieve faster symptom relief through direct local delivery
of a medication to the nasal tissues.
Azelastine is a second generation H1-antihistamine [4]
that is currently marketed as a topically applied agent
(i.e. nasal spray). Numerous studies have demonstrated its
ability to provide significant improvement in the symp-
toms of SAR compared to placebo [5-9]. Azelastine is be-
lieved to exert its effects through alteration of the activities
of mast cells, eosinophils, and neutrophils and inhibition
of the synthesis or expression of leukotrienes, kinins, cyto-
kines, and chemokines [10-13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Restricted medications and required washout times
Prohibited medication Time frame prohibited
prior to first priming
visit and thereafter
Decongestants Within 48 hours
Topical glucocorticoids Within 14 days
Tricyclic antidepressants Within 14 days
Tranquilizers Within 14 days
Monoamine oxidase inhibitors Within 14 days
Long acting β-2 agonists Within 14 days
Glucocorticoids (inhaled, oral or intravenous) Within 28 days
Glucocorticoids (intramuscular or intra-articular) Within 84 days
Antihistamines Within 7 days
Leukotrienes antagonists Within 7 days
Theophylline Within 7 days
Non-steroidal anti-inflammatory drugs Within 7 days
Systemic antibodies Within 7 days
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with the natural exposure to aeroallergens give rise to con-
siderable inter-study variations when assessing the efficacy
and onset of action of various drugs to treat SAR; there-
fore, this study was conducted in the highly controlled en-
vironment of the Environmental Exposure Unit (EEU).
The EEU is a well-validated and internationally recognized
controlled allergen challenge facility located in Kingston,
ON Canada [14-16]. The EEU allows for large groups of
clinical trial participants to be simultaneously exposed to
controlled levels of airborne allergens such as ragweed or
grass pollen. Within this specially designed room, allergen
levels can be precisely maintained at predetermined levels
and environmental variables such as air quality, temper-
ature, humidity and CO2 levels are tightly regulated [15].
With the ability to control these variables, study conditions
can be reproduced on different days at any time of the year
with the same or different study participants, something
that cannot be achieved with any other research model
for allergic rhinitis. Utilizing this model thus yields more
precise results for direct comparisons of different treat-
ment modalities [14]. Over the past decade, the EEU has
gained international acceptance for the clinical research
conducted in Kingston with over 20 publications in top re-
search journals (recent references indicated) [17-23].
Azelastine hydrochloride has been marketed as a pre-
scription product in the United States since 1996 under
the trade name AstelinW. A new dosing regimen of 1 spray
per nostril twice daily was approved in 2006 for the treat-
ment of SAR [24] and thus was administered in this study.
The objective of the current evaluation was to deter-
mine the onset of action of azelastine nasal spray, com-
pared to established oral antihistamines (loratadine 10 mg
and cetirizine 10 mg tablets), for the relief of symptoms of
SAR. This study further allowed for the comparison of
topical versus oral application of medication.
Methods
Study participants
Participants were healthy male and female volunteers
between the ages of 18 and 65 with a history of SAR to
ragweed for the preceding two consecutive pollen sea-
sons. Atopic status was confirmed with a positive response
to a skin prick test to ragweed allergen at screening or
within 12 months of the screening visit (defined as a wheal
diameter greater than or equal to 3 mm larger than the
diluent control).
Enrolled female participants of childbearing potential
used a medically acceptable form of birth control for at
least 1 month prior to screening. Those who were not
sexually active consented to use a double-barrier method
should they become sexually active during the study. Fe-
males who were pregnant, lactating or had the intention
of becoming pregnant were not enrolled.Participants with a history of hypersensitivity to aze-
lastine, loratadine, or cetirizine or were known to be non-
responsive to antihistamines were excluded. Participants
with relevant concomitant disease (chronic sinusitis) or
nasal structural abnormalities causing greater than 50%
obstruction were also excluded. Furthermore, participants
who suffered from an acute illness that could have inter-
fered with the conduct of the study within 7 days of any
pollen exposure visit were excluded. Also excluded were
participants with asthma who required more than occa-
sional use (<3 times per week) of inhaled short-acting β-2
agonists and any participants who took restricted medica-
tions within the proscribed time period prior to their first
priming visit (See Table 1).
Participants with clinically significant histories of hema-
tological, renal, endocrine, pulmonary, gastrointestinal,
cardiovascular, hepatic, psychiatric, or neurologic malig-
nancies within the last 5 years were excluded. Other ex-
clusion criteria include alcoholism or drug abuse within
2 years prior to the screening visit; regular use within
6 months of any type of tobacco product(s) or any smok-
ing cessation nicotine-containing product; participation in
any other trials involving investigational or marketed prod-
ucts within 30 days prior to the screening visit; and history
of a positive test for HIV, TB (not due to vaccination),
hepatitis B (not due to vaccination), or hepatitis C.
Study design
This Phase IV trial was a randomized, single-center,
double-blind, placebo-controlled, double-dummy, four-
way crossover study. All participants provided written, in-
formed consent prior to study entry. The trial protocol,
amendments and informed consent forms were approved
by the Queen’s University Health Sciences and Affiliated
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was conducted according to Good Clinical Practice stan-
dards and International Conference on Harmonization
guidelines.
The study was conducted in the Environmental Exposure
Unit (EEU) and consisted of a screening visit, a priming
period and four dosing/exposure periods with a 13-day
washout between each period.
Eligibility was determined at the screening visit, during
which written informed consent was obtained. The first
priming visit occurred within 16 days of the screening visit.
Participants attended a minimum of one up to a max-
imum of five priming visits, where they were exposed to
ragweed pollen in the EEU to establish an adequate level
of allergic reactivity. Participants underwent up to 3 hours
of pollen exposure at each visit, during which symptoms
were recorded on diary cards calculating the Total Nasal
Symptom Score (TNSS) every 30 minutes.
The TNSS was comprised of the following symptoms of
allergic rhinitis: sneezing, runny nose, and itchy nose, with
each individual symptom rated on a 4-point scale (0 = none,
1 =mild, 2 =moderate, 3 = severe; See Table 2). Thus, the
maximum TNSS that could be achieved was 9. Also docu-
mented were symptom score ratings for nasal obstruction,
itchy eyes and teary eyes.
A minimum TNSS of 4 must have been obtained at the
90 minute symptom evaluation during a priming visit;
those who did not meet this criterion were asked to return
for another priming visit up to a maximum of five visits.
Participants who met this criterion during at least one
priming visit returned within 7 days for the first of four
dosing periods.
Each dosing period consisted of an 8 hour allergen chal-
lenge. Participants were asked to score symptoms on diary
cards every 30 minutes during a 2 hour baseline allergen
challenge period. At 90 minutes, the participant must have
had a minimum TNSS of 4 in order to be randomized into
the study. Participants were randomized to the sequence of
administration of one dose of each of the four study medi-
cations – azelastine (A), loratadine (L), cetirizine (C), or
placebo (P). Randomization occurred in a 1:1:1:1 ratio, with
approximately 17 participants randomized to each of the
treatment sequences (Figure 1).Table 2 Symptoms score definitions
Score Grade Guideline
0 None No sign/symptom is evident
1 Mild Sign/symptom clearly present,
but minimal awareness; easily tolerated
2 Moderate Definite awareness of sign/symptom
that is bothersome, but tolerable
3 Severe Sign/symptom that is hard to tolerate;
causes interference with activities
during the challenge sessionAt 2 hours, participants were administered their as-
signed treatment, receiving oral medication with placebo
nasal spray, nasal medication with placebo tablet, or pla-
cebo nasal spray and placebo tablet as control. Following
dosing, the allergen challenge continued for 6 hours and
participants were asked to score symptoms on diary cards
every 15 minutes for the first 2 hours and every 30 minutes
for the remaining 4 hours. Participants also completed an
overall assessment of treatment efficacy diary card. Lastly,
participants were questioned at the end of each dosing
period with regards to the occurrence of adverse events.
Statistical analysis
The Per Protocol (PP) population consisted of all partici-
pants who completed all four dosing periods. A priori, it
was established that data from these participants were
used for the primary comparison of the four treatment
groups. The Intent-To-Treat (ITT) population consisted
of participants who provided at least one estimate of an
efficacy parameter after the first dose of study treatment
and this data was used as support in the estimation of
the onset of action and efficacy of the four treatments.
Absolute values and change from baseline were summa-
rized for TNSS, the individual component symptoms
(sneezing, runny nose, and itchy nose), average TNSS over
the last 2 hours, nasal obstruction, teary eyes, and itchy
eyes. The data were described by summary statistics.
Mean TNSS, sneezing, runny nose, itchy nose, stuffy nose,
teary eyes, and itchy eyes and the corresponding mean
change from the baseline were plotted across time.
For each time point, mean change from baseline for
azelastine, cetirizine, and loratadine was compared to mean
change from baseline for placebo. Corresponding 95% con-
fidence intervals (CI) were presented. Differences between
mean change from baseline and corresponding 95% CI
were also presented for treatment differences between aze-
lastine and cetirizine and between azelastine and loratadine.
For continuous variables, estimates and p-values were
obtained from a mixed effects model with fixed effects for
sequence, period and treatment and random effects for par-
ticipant within sequence. Statistical tests were performed at
a nominal two-sided level of P = 0.05. No adjustments for
multiplicity were made. For overall assessment of efficacy,
estimates and p-values were obtained from a mixed effects
cumulative logit proportional odds model with fixed effects
for sequence, period and treatment and random effects for
participant within sequence. All statistical analyses were
performed using SASW software, version 9.1.
Results
A total of 70 participants were randomized and all partici-
pants took at least one dose of study drug and thus re-
ceived at least one efficacy evaluation. All 70 participants
were included in the ITT population; however 4
Figure 1 Study diagram.
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failing to complete all four dosing periods or for lacking
the required symptom score. The demographic character-
istics of study participants and the baseline symptom
scores prior to dosing period 1 are summarized in Table 3
and were similar among the four treatment sequences.
The primary efficacy parameter was the onset of action
measured by the change from baseline in TNSS. For each
of the active treatment groups, onset of action was defined
as the time after treatment when the drug demonstrated
a statistically significant change that was maintained until
the next consecutive time point compared to placebo.
Azelastine showed a statistically significant improvement in
the TNSS at 15 minutes compared with placebo (p < 0.001),
and the effect was durable at each time point during the
6 hours post-dose (p < 0.001). Cetirizine and loratadine
displayed a statistically significant improvement in the
TNSS at 60 minutes (p = 0.015) and 75 minutes (p = 0.034),
respectively, compared with placebo; the effect was durable
at each time point thereafter through 6 hours post dose
(p < 0.001 and p ≤ 0.011, respectively). The mean TNSS
and mean change from baseline in TNSS for all three medi-
cations and placebo are shown in Figure 2.
Azelastine was more effective than cetirizine at each
time point from 15 to 60 minutes post-dose (95%CI ≤ -0.2)
and more effective than loratadine at each time point from
15 minutes to 5 hours post dose (95%CI ≤ -0.1). The raw
mean changes from baseline in TNSS ranged from -0.7 (at
15 minutes) to -2.1 (at 90 minutes) for placebo, from -0.8
(at 15 minutes) to -3.8 (at 2.5, 3.5, and 4 hours) for
cetirizine, from -0.7 (at 15 minutes) to -3.4 (at 2.5 hours)
for loratadine, and from -1.5 (at 15 minutes) to -4.3 (at
120 minutes) for azelastine. The greater change of 0.7 in
azelastine at 15 minutes post-dose in comparison tocetirizine indicates an immediate and clinically relevant in-
crease in tolerability of symptoms; which would translate
into decreased interference with daily functioning.
The secondary efficacy parameter was measured by
four components: change from baseline for the individ-
ual components of the symptoms constituting the TNSS
(sneezing, itchy nose, and runny nose); the average
TNSS change from baseline over the last 2 hours of the
allergen challenge; the relief of nasal obstruction, teary
eyes, itchy eyes; and the overall participant assessment
of efficacy.
Figure 3 illustrates the mean component scores for each
medication for sneezing, nasal itching and runny nose.
Azelastine showed significant improvement in the sneezing
score and the itchy nose score at 15 minutes compared with
placebo (p = 0.007), and at 30 minutes for runny nose com-
pared with placebo (p < 0.001). This effect was durable at
each time point during the 6 hours post-dose (p ≤ 0.047,
p < 0.001, and p < 0.001, respectively). Cetirizine showed
significant improvement in the sneezing score and itchy
nose score at 75 minutes compared with placebo (p = 0.026
and p < 0.001, respectively) and at 30 minutes for runny
nose compared with placebo (p = 0.043). Loratadine showed
statistically significant improvements in the sneezing score
and itchy nose score at 105 minutes compared to placebo
(p = 0.002 and p = 0.013, respectively) and at 75 minutes for
the runny nose score compared with placebo (p = 0.016).
The raw mean changes from baseline in sneezing score
ranged from -0.3 (15 minutes) to -1.3 (2.5 hours) for
cetirizine, from -0.3 (15 minutes) to -1.1 (2.5 hours) for
loratadine, and from -0.7 (15 minutes) to -1.4 (105 minutes)
for azelastine. The raw mean changes from baseline in itchy
nose score ranged from -0.3 (15 minutes) to -1.3 (2.5,
3.0, 3.5, and 6.0 hours) for cetirizine, from -0.2 (15 minutes)






Age (yrs) Baseline sneezing score
Mean 35.0 Mean 2.1
Std. 9.88 Std. 0.97
Median 34.5 Median 2.0
Min. to Max. 21-63 Min. to Max. 0-3
Gender Baseline runny nose score
Male 27 (41%) Mean 2.7
Female 39 (59%) Std. 0.44
Ethnicity Median 3.0
Hispanic 0 (0%) Min. to Max. 2-3
Not Hispanic 66 (100%) Baseline nasal itching score
Race Mean 2.6
Caucasian 64 (97%) Std. 0.55
Black 0 (0%) Median 3.0
Asian 2 (3%) Min. to Max. 1-3
American Indian/
Alaska Native
0 (0%) Baseline stuffy nose score
Native Hawaiian/
Other Pacific Islander
0 (0%) Mean 2.6
Other 0 (0%) Std. 0.52
Height (cm) Median 3.0
Mean 168.2 Min. to Max. 1-3
Std. 8.70 Baseline teary eyes score
Median 168.0 Mean 2.0
Min. to Max. 153-188 Std. 0.73
Weight (kg) Median 2.0
Mean 79.6 Min. to Max. 1-3
Std. 16.77 Baseline itchy eyes score
Median 79.0 Mean 2.4
Min. to Max. 50-125 Std. 0.75
BMI (kg/m2) Median 3.0
Mean 28.11 Min. to Max. 1-3
Std. 5.478 Baseline total nasal symptom score
Median 27.04 Mean 7.4
Min. to Max. 19.1-42.8 Std. 1.21
Median 7.0
Min. to Max. 5-9
Baseline is the 90-minute evaluation after the beginning of the allergen
challenge for the baseline period prior to dosing period 1.
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(15 minutes) to -1.5 (2.5 hours) for azelastine. The raw
mean changes from baseline in runny nose ranged
from -0.2 (15 minutes) to -1.4 (4 hours) for cetirizine,
from -0.2 (15 minutes) to -1.1 (120 minutes and 2.5, 3.0,3.5, 4.0, and 4.5 hours) for loratadine, and from -0.4
(15 minutes) to -1.5 (120 minutes) for azelastine.
Azelastine was more effective than cetirizine at each
time point from 15 to 45 minutes post-dose and more
effective than loratadine at each time point from 15 to
60 minutes and 105 to 120 minutes post dose for the
sneezing score. It was also more effective than cetirizine at
each time point from 30 to 60 minutes post-dose and
more effective than loratadine at each time point from
15 minutes to 5 hours post dose with the exception of the
3 hour time point for the itchy nose score. Azelastine was
more effective than cetirizine at each time point from 15
to 60 minutes post-dose and more effective than loratadine
at each time point from 30 minutes to 6 hours post dose
with the exception of 4.5 hours for the runny nose score.
The change from baseline for azelastine, cetirizine, and
loratadine were significantly different from the change from
baseline for placebo (p < 0.001) for the average TNSS over
the last 2 hours of the allergen challenge. No statistically
significant differences were observed between azelastine
and cetirizine (p = 0.866) nor between azelastine and lorat-
adine (p = 0.066).
Azelastine showed a statistically significant improve-
ment in the stuffy nose score and itchy eyes score at
15 minutes compared with placebo (p = 0.029, p = 0.028,
respectively), and at 45 minutes in the teary eyes score
compared with placebo (p = 0.002). The effect was durable
for each time point in the 6 hours post dose for all three
symptoms (p ≤ 0.029, p ≤ 0.006, and p ≤ 0.049, respectively),
with the exception of at 75 minutes for the teary eyes score.
Cetirizine showed statistically significant improvement in
the stuffy nose score at 60 minutes (p = 0.029), in the itchy
eyes score at 15 minutes (p = 0.039), and in the teary eyes
score at 105 minutes (p = 0.001) compared with placebo.
Loratadine showed a statistically significant improvement in
the stuffy nose score at 3 hours (p < 0.001), and in the teary
eyes score at 105 minutes (p = 0.005) compared with pla-
cebo. Loratadine showed a statistically significant improve-
ment at 15 minutes and 45 minutes in the itchy eyes score
compared with placebo (p = 0.028 and p = 0.033, respec-
tively), the effect was durable at each time point at
75 minutes through 6 hours post-dose (p ≤ 0.016).
Azelastine was more effective than cetirizine at 15 min-
utes post-dose and more effective than loratadine at each
time point from 15 to 60 minutes post dose except at the
30 minute time point for the stuffy nose score. Azelastine
was also more effective than cetirizine and loratadine at
45 and 60 minutes post-dose for the itchy eyes score. No
statistically significant differences were observed in relief
of teary eyes symptoms between azelastine and cetirizine
or loratadine at any time point.
Better overall assessment of efficacy was shown for
azelastine, cetirizine, and loratadine compared to placebo
(p < 0.001, p < 0.001, and p = 0.003, respectively). The
Figure 2 Change in TNSS over time; comparison between Azelastine (AAA), Cetirizine (CCC) and Loratadine (LLL) vs. Placebo (PPP). A)
Mean (95% confidence interval) TNSS and B) Mean change from baseline (95% confidence interval) in TNSS vs. Time (minutes) from dosing.
Ellis et al. Allergy, Asthma & Clinical Immunology 2013, 9:16 Page 6 of 10
http://www.aacijournal.com/content/9/1/16overall assessment of efficacy was completed on a 4-point
scale (1 = very good, 2 = good, 3 = satisfactory, 4 = insuffi-
cient). Of the 66 participants who completed all four dos-
ing treatments, the overall assessment of efficacy was rated
as very good or good by 30 participants for azelastine, 34
participants for cetirizine, and 20 participants for
loratadine compared to 12 participants for placebo. Overall
assessment of efficacy for azelastine was similar to
cetirizine (p = 0.313) but significantly better than loratadine
(p = 0.014). Detailed assessment of overall efficacy for all
three drugs and placebo is shown in Table 4.
Azelastine, cetirizine, and loratadine were well tolerated,
and few adverse events were reported. For azelastine, all
except 1 of the adverse events were mild or moderate in
intensity, and all except 2 adverse events were considered
not possibly related to the study medication. The severe
adverse event was sinus headache, and the 2 possibly re-
lated adverse events were moderate somnolence and milddysgeusia. The most commonly reported adverse event was
myalgia (3 subjects), followed by headache (2 subjects),
diarrhea (2 subjects), and nasal congestion (2 subjects). For
cetirizine, all except 1 of the adverse events were mild or
moderate in intensity, and all adverse events were consid-
ered not possibly related to the study medication by the in-
vestigator. The severe adverse event was abdominal pain.
No adverse event was reported by more than 1 subject. For
loratadine, all adverse events were mild or moderate in in-
tensity, and all except 1 adverse event were considered not
possibly related to the study medication. The possibly re-
lated adverse event was mild urticaria. The only adverse
event reported by more than 1 subject was upper respira-
tory tract infection. For placebo, all adverse events were
mild or moderate in intensity and considered not possibly
related to study medication. No adverse event was reported
by more than one subject. No participants elected to dis-
continue the study due to adverse events.
Figure 3 Change in individual symptom components over time between Azelastine (AAA), Cetrizine (CCC) and Loratadine (LLL) vs.
Placebo (PPP). Mean (95% confidence interval) component score vs. Time from dosing for A) Sneezing B) Itchy nose C) Runny nose.
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Table 4 Participant ratings of overall effectiveness of
the medication
Placebo Cetirizine Loratadine Azelastine
(N = 66) (N = 66) (N = 66) (N = 66)
Very good 6 (9%) 14 (21%) 8 (12%) 11 (17%)
Good 6 (9%) 20 (30%) 12 (18%) 19 (29%)
Satisfactory 10 (15%) 20 (30%) 22 (33%) 21 (32%)
Insufficient 44 (67%) 12 (18%) 24 (36%) 15 (23%)
Mean 3.4 2.5 2.9 2.6
Std. 0.99 1.03 1.02 1.02
Median 4.0 2.0 3.0 3.0
Min. to Max. 1-4 1-4 1-4 1-4
P value vs. placebo <0.001 0.003 <0.001
P-values and estimates obtained from a mixed effects cumulative logit
proportional odds model with fixed effects for sequence, period, and
treatment and random effects for subject within sequence.
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This study was designed to characterize the exact onset
of action for allergic rhinitis symptom relief by azelastine
(1 spray per nostril) compared to the onset of action of
established oral antihistamines loratadine 10 mg and
cetirizine 10 mg tablets.
Azelastine’s onset of action for TNSS, occurring at
15 minutes, was faster than the onset of action for cetirizine
and loratadine. This rapid onset of action is consistent
with previous environmental exposure facility trials [25,26],
which also demonstrated an azelastine onset of action for
TNSS of 15 minutes.
Azelastine demonstrated greater symptom score reduc-
tion than cetirizine during the immediate period post-dose
and better efficacy than loratadine for the majority of the
period post-dose (Figure 2). This suggests that azelastine
may be preferential to oral antihistamines for the rapid
relief of SAR symptoms. In vitro studies using rat IgE-
producing hybridoma FE-3 cells have shown azelastine to
have an inhibitory effect on IgE secretion [27]. While this
has not been shown with human cells nor in vivo, it is pos-
sible that azelastine may confer rapid relief through inhi-
bition of allergen-antibody interactions associated with
SAR symptoms in the upper airway. Furthermore, the top-
ical application of azelastine may allow for more rapid ab-
sorption in comparison to the orally taken cetirizine and
loratadine, thereby accounting for its faster onset of action.
Azelastine’s onset of action for the relief of the individ-
ual components of TNSS (sneezing, itchy nose, and
runny nose) was also faster than the onset of action for
cetirizine and loratadine. Azelastine achieved durable
significant improvement at 15 minutes for sneezing and
itchy nose and at 30 minutes for runny nose. Cetirizine
and loratadine did not achieve a durable significant re-
sponse for all components until at least 60 minutes and
75 minutes post-dose, respectively. Overall, azelastinewas able to decrease the TNSS component scores more
quickly, and was able to maintain the decreased score at
a level comparable to or better than cetirizine and
loratadine over the ensuing 6 hours post-dose (Figure 3).
It should be noted that the oral medications were as or
almost as effective over the last 2 hours of the allergen
challenge in treating TNSS. There were no statistically
significant differences between the average TNSS change
from baseline over the last two hours for all three medi-
cations. Thus, azelastine provided comparable relief of
TNSS symptoms during the later period post-dose.
Azelastine showed a faster onset of action for the relief
of stuffy nose and teary eyes than cetirizine and loratadine.
Faster relief of stuffy nose is significant as nasal congestion
has been reported as the most bothersome rhinitis symp-
tom by more than half of 3206 patients surveyed with his-
tories of rhinitis [28]. Azelastine and cetirizine both
showed an onset of action of 15 minutes for the relief of
itchy eyes, which was faster than the onset of action for
loratadine. For the overall participant satisfaction in treat-
ment, azelastine was comparable to cetirizine and statisti-
cally superior to loratadine (Table 4).
No safety concerns were identified in this study, with
all active preparations being safe and well tolerated.
The effectiveness and onset of action of cetirizine 10 mg
and loratadine 10 mg compared to placebo has previously
been studied [29,30], with results that are consistent with
the findings of this trial. Both studies found the onset of
action for multi-component symptom scores to be ap-
proximately 1 hour for cetirizine and approximately
3 hours for loratadine. This is consistent with the current
results as cetirizine’s onset of action occurred at approxi-
mately 1 hour for most symptoms evaluated. Loratadine’s
onset of action occurred more quickly in this trial than in
these previous trials; however, its onset of action was con-
sistently longer than cetirizine and azelastine, not occur-
ring until at least 75 minutes for all symptoms. One point
to consider as well is that the double-dummy nature of
these types of studies may lead to enhanced efficacy in the
antihistamine arms due to the known therapeutic benefits
derived from nasal saline (placebo) application that would
be delivered to the oral antihistamine treated participants.
Other trials have examined azelastine (2 sprays per
nostril) in comparison to cetirizine 10 mg for the treat-
ment of seasonal allergic rhinitis [31,32]. These studies
examined TNSS scores over the course of 14 days and
therefore onset of action was not the main objective.
Azelastine showed greater improvements in TNSS
symptoms than cetirizine over the 14 days in both stud-
ies. A more appreciable difference in total TNSS may
have been observed in this study had the maximum
TNSS score been greater than 9.
Azelastine (2 sprays per nostril) has also been studied
for its efficacy in conjunction with loratadine 10 mg
Ellis et al. Allergy, Asthma & Clinical Immunology 2013, 9:16 Page 9 of 10
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compared to azelastine alone and desloratadine 5 mg.
This study found azelastine to be an effective alternative
for those with poor response to loratadine. However, the
individual efficacies of azelastine and loratadine were
not compared in this study.
Conclusions
To our knowledge, this is the first trial directly comparing
the onset of action of azelastine, cetirizine, and loratadine
for the treatment of SAR. The unique operational charac-
teristics of the EEU facilitated this head-to-head compari-
son. This study supports the rapid onset of action of
azelastine nasal spray to relieve SAR symptoms; more
quickly than oral antihistamines. The faster onset com-
bined with comparable levels of symptom relief suggest
that azelastine could be used as a replacement for oral an-
tihistamines in the management of SAR.
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